{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:10:59Z","timestamp":1791414659581,"version":"4.3.3"},"reference-count":72,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.bbadis.2016.01.009","type":"journal-article","created":{"date-parts":[[2016,1,13]],"date-time":"2016-01-13T06:19:23Z","timestamp":1452665963000},"page":"754-762","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene"],"prefix":"10.1016","volume":"1862","author":[{"given":"Andr\u00e9 B.P. van","family":"Kuilenburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9828-4459","authenticated-orcid":false,"given":"Michael W.T.","family":"Tanck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doreen","family":"Dobritzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lida","family":"Zoetekouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lois-Lee","family":"Dekkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Roelofsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutger","family":"Meinsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Machteld","family":"Wymenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Kulik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"B\u00fcchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raoul C.M.","family":"Hennekam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo R.","family":"Largiad\u00e8r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbadis.2016.01.009_bb0005","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1056\/NEJMoa043116","article-title":"Capecitabine as adjuvant treatment for stage III colon cancer","volume":"352","author":"Twelves","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0010","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMra040958","article-title":"Systemic therapy for colorectal cancer","volume":"352","author":"Meyerhardt","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0015","first-page":"2203","article-title":"Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile","volume":"47","author":"Heggie","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0020","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF03257473","article-title":"Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy","volume":"51","author":"van Kuilenburg","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0025","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ejca.2003.12.004","article-title":"Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil","volume":"40","author":"van Kuilenburg","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbadis.2016.01.009_bb0030","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0065-2571(00)00011-X","article-title":"Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil","volume":"41","author":"Johnson","year":"2001","journal-title":"Adv. Enzym. Regul."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0035","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.bjc.6690098","article-title":"Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity","volume":"79","author":"Milano","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbadis.2016.01.009_bb0040","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/ijc.29025","article-title":"Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity","volume":"136","author":"Froehlich","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbadis.2016.01.009_bb0045","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1038\/bjc.2013.262","article-title":"Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity","volume":"108","author":"Loganayagam","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbadis.2016.01.009_bb0050","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2217\/pgs.13.116","article-title":"DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis","volume":"14","author":"Terrazzino","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.bbadis.2016.01.009_bb0055","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1200\/JCO.2013.51.1857","article-title":"Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis","volume":"32","author":"Rosmarin","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0060","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju298","article-title":"DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147)","volume":"106","author":"Lee","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0065","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00439-010-0879-3","article-title":"Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity","volume":"128","author":"van Kuilenburg","year":"2010","journal-title":"Hum. Genet."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0070","first-page":"4705","article-title":"Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene","volume":"6","author":"van Kuilenburg","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0075","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2217\/pgs.09.28","article-title":"Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment","volume":"10","author":"Amstutz","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.bbadis.2016.01.009_bb0080","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ijc.10599","article-title":"Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation","volume":"101","author":"van Kuilenburg","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbadis.2016.01.009_bb0085","doi-asserted-by":"crossref","first-page":"519","DOI":"10.4155\/bio.14.304","article-title":"Improved pharmacodynamic assay for dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells","volume":"7","author":"Pluim","year":"2015","journal-title":"Bioanalysis"},{"key":"10.1016\/j.bbadis.2016.01.009_bb0090","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/clpt.2013.172","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing","volume":"94","author":"Caudle","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0095","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/clpt.2011.34","article-title":"Pharmacogenetics: from bench to byte \u2014 an update of guidelines","volume":"89","author":"Swen","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0100","first-page":"389","article-title":"Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency","volume":"13","author":"van Staveren","year":"2013","journal-title":"Pharm. J."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0105","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.1999.17.4.1105","article-title":"Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage","volume":"17","author":"Gamelin","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0110","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00280-010-1282-4","article-title":"DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity","volume":"67","author":"Yang","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/PL00008711","article-title":"Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency","volume":"104","author":"van Kuilenburg","year":"1999","journal-title":"Hum. Genet."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0120","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1042\/bj3640157","article-title":"Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure","volume":"364","author":"van Kuilenburg","year":"2002","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0125","first-page":"1096","article-title":"Identification of a novel disease-causing mutation (100delA) in the dihydropyrimidine dehydrogenase gene","volume":"1","author":"van Kuilenburg","year":"2002","journal-title":"Int. Arch. Biocsi."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0130","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1515\/BC.2005.038","article-title":"Identification of three novel mutations in the dihydropyrimidine dehydrogenase gene associated with altered pre-mRNA splicing or protein function","volume":"386","author":"van Kuilenburg","year":"2005","journal-title":"Biol. Chem."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0135","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1158\/0008-5472.CAN-13-2482","article-title":"Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity","volume":"74","author":"Offer","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0140","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1158\/0008-5472.CAN-12-3858","article-title":"Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity","volume":"73","author":"Offer","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0145","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.1158\/1078-0432.CCR-04-1784","article-title":"Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals","volume":"11","author":"Seck","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0150","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/FTD.0000000000000109","article-title":"Determination of DPYD enzyme activity in Korean population","volume":"37","author":"Shin","year":"2015","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0155","article-title":"Genotype\u2013phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction","author":"Gentile","year":"2015","journal-title":"Pharm. J."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0160","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.2217\/pgs.14.126","article-title":"Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio","volume":"15","author":"Sistonen","year":"2014","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.bbadis.2016.01.009_bb0165","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/clinchem\/46.1.9","article-title":"Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency","volume":"46","author":"van Kuilenburg","year":"2000","journal-title":"Clin. Chem."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0170","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/clinchem\/46.12.1916","article-title":"Defects in pyrimidine degradation identified by HPLC-electrospray tandem mass spectrometry of urine specimens or urine-soaked filter paper strips","volume":"46","author":"van Lenthe","year":"2000","journal-title":"Clin. Chem."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0175","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1373\/clinchem.2003.026229","article-title":"Quantification of 5,6-dihydrouracil by HPLC-electrospray tandem mass spectrometry","volume":"50","author":"van Kuilenburg","year":"2004","journal-title":"Clin. Chem."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0180","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/emboj\/20.4.650","article-title":"Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil","volume":"20","author":"Dobritzsch","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0185","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0190","author":"DeLano"},{"key":"10.1016\/j.bbadis.2016.01.009_bb0195","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/genetics\/49.1.49","article-title":"The interaction of selection and linkage. I. General considerations; heterotic models","volume":"49","author":"Lewontin","year":"1964","journal-title":"Genetics"},{"key":"10.1016\/j.bbadis.2016.01.009_bb0200","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/hdy.1974.89","article-title":"Estimation of linkage disequilibrium in randomly mating populations","volume":"33","author":"Hill","year":"1974","journal-title":"Heredity (Edinb.)"},{"key":"10.1016\/j.bbadis.2016.01.009_bb0205","author":"Sinnwell"},{"key":"10.1016\/j.bbadis.2016.01.009_bb0210","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1479-7364-1-1-7","article-title":"Gametic phase estimation over large genomic regions using an adaptive window approach","volume":"1","author":"Excoffier","year":"2003","journal-title":"Human Genomics"},{"key":"10.1016\/j.bbadis.2016.01.009_bb0215","series-title":"R: A Language and Environment for Statistical Computing.","author":"RCoreTeam","year":"2014"},{"key":"10.1016\/j.bbadis.2016.01.009_bb0220","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1432-1033.1989.tb14743.x","article-title":"Purification and properties of 5,6-dihydropyrimidine amidohydrolase from calf liver","volume":"181","author":"Kautz","year":"1989","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0225","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1432-1033.1994.tb19951.x","article-title":"Purification, characterization and inhibition of dihydropyrimidinase from rat liver","volume":"219","author":"Kikugawa","year":"1994","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0230","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nature02168","volume":"426","author":"The International HapMap Project","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2016.01.009_bb0235","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/316170a0","article-title":"Beta-hairpin families in globular proteins","volume":"316","author":"Sibanda","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2016.01.009_bb0240","first-page":"5433","article-title":"Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy","volume":"53","author":"Lu","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0245","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.1994.12.11.2248","article-title":"Population study of dihydropyrimidine dehydrogenase in cancer patients","volume":"12","author":"Etienne","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0250","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/0009-9236(95)90171-X","article-title":"Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy","volume":"58","author":"Lu","year":"1995","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0255","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/00007691-199904000-00002","article-title":"Dihydropyrimidine dehydrogenase activity in a Korean population","volume":"21","author":"Sohn","year":"1999","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0260","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.1158\/1078-0432.CCR-06-0747","article-title":"Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians","volume":"12","author":"Mattison","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0265","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/clpt.2013.69","article-title":"A DPYD variant (Y186C) in individuals of African ancestry is associated with reduced DPD enzyme activity","volume":"94","author":"Offer","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0270","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1158\/1078-0432.CCR-05-0217","article-title":"Dihydropyrimidine dehydrogenase activity in 150 healthy Japanese volunteers and identification of novel mutations","volume":"11","author":"Ogura","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0275","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ejca.2006.09.017","article-title":"Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin","volume":"43","author":"van Kuilenburg","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbadis.2016.01.009_bb0280","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/0006-2952(93)90505-Q","article-title":"Comparison of dihydropyrimidine dehydrogenase from human, rat, pig and cow liver. Biochemical and immunological properties","volume":"46","author":"Lu","year":"1993","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0285","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/0006-2952(93)90615-4","article-title":"5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo","volume":"46","author":"Spector","year":"1993","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0290","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1158\/1078-0432.CCR-03-0374","article-title":"Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test","volume":"10","author":"Mattison","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0295","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1158\/1078-0432.CCR-05-2020","article-title":"The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil","volume":"12","author":"Mattison","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0300","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s00280-011-1661-5","article-title":"Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency","volume":"68","author":"van Staveren","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0305","doi-asserted-by":"crossref","DOI":"10.1080\/15257770600894576","article-title":"Activity of pyrimidine degradation enzymes in normal tissues","author":"van Kuilenburg","year":"2006","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.bbadis.2016.01.009_bb0310","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/(SICI)1096-8628(19980724)78:4<336::AID-AJMG6>3.0.CO;2-J","article-title":"Population and family studies of dihydropyrimidinuria: prevalence, inheritance mode, and risk of fluorouracil toxicity","volume":"78","author":"Sumi","year":"1998","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0315","first-page":"4363","article-title":"Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity","volume":"9","author":"van Kuilenburg","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0320","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.bbadis.2010.03.013","article-title":"Dihydropyrimidinase deficiency: phenotype, genotype and structural consequences in 17 patients","volume":"1802","author":"van Kuilenburg","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbadis.2016.01.009_bb0325","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/FPC.0b013e3282f01788","article-title":"Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism","volume":"17","author":"Thomas","year":"2007","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.bbadis.2016.01.009_bb0330","first-page":"1149","article-title":"Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency","volume":"7","author":"van Kuilenburg","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0335","first-page":"507","article-title":"Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver","volume":"2","author":"Chazal","year":"1996","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0340","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1158\/1535-7163.MCT-06-0327","article-title":"Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance","volume":"5","author":"Morel","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0345","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1158\/1078-0432.CCR-10-2209","article-title":"Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer","volume":"17","author":"Deenen","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbadis.2016.01.009_bb0350","doi-asserted-by":"crossref","first-page":"303","DOI":"10.4149\/neo_2009_04_303","article-title":"Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy","volume":"56","author":"Kleibl","year":"2009","journal-title":"Neoplasma"},{"key":"10.1016\/j.bbadis.2016.01.009_bb0355","doi-asserted-by":"crossref","first-page":"e4003","DOI":"10.1371\/journal.pone.0004003","article-title":"Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients","volume":"3","author":"Gross","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.bbadis.2016.01.009_bb0360","doi-asserted-by":"crossref","first-page":"827989","DOI":"10.1155\/2014\/827989","article-title":"Influence of DPYD genetic polymorphisms on 5-fluorouracil toxicities in patients with colorectal cancer: a meta-analysis","volume":"2014","author":"Li","year":"2014","journal-title":"Gastroenterol. Res. Pract."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443916000107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443916000107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T19:40:12Z","timestamp":1718307612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443916000107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":72,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0925443916000107"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2016.01.009","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2016.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}